Mozobil (plerixafor) is a small molecule pharmaceutical. Plerixafor was first approved as Mozobil on 2008-12-15. It is used to treat multiple myeloma and non-hodgkin lymphoma in the USA. It has been approved in Europe to treat hematopoietic stem cell transplantation, lymphoma, and multiple myeloma. The pharmaceutical is active against C-X-C chemokine receptor type 4. In addition, it is known to target C-C chemokine receptor type 4 and atypical chemokine receptor 3. Mozobil's patent is valid until 2023-07-22 (FDA).
|Indication||hematopoietic stem cell transplantation, lymphoma, multiple myeloma, non-hodgkin lymphoma|
|Drug Class||Cxcr4 antagonists|